Abstract
To evaluate the efficacy of long-term administration of acyclovir as prophylaxis against varicella-zoster virus (VZV) reactivation, we analyzed the medical records of 86 consecutive adult patients who obtained engraftment after allogeneic hematopoietic stem cell transplantation from January 1996 to March 2000. We started long-term low-dose (400âmg/day) oral administration of acyclovir in June 1999, and this was continued until the end of immunosuppressive therapy after transplantation. There was no breakthrough reactivation of VZV in patients receiving acyclovir. Five patients who were receiving cyclosporine or prednisolone developed VZV reactivation after discontinuing acyclovir. With this prophylaxis, the cumulative incidence of VZV reactivation at 1 year after transplantation decreased from 33% to 10% (Pâ=â0.025). On multivariate analysis, the use of long-term acyclovir was identified as a significant independent parameter for the development of VZV reactivation. These findings suggest the efficacy of long-term prophylaxis with low-dose acyclovir. Resumption of acyclovir upon restarting immunosuppressive therapy might be important for the further prevention of VZV reactivation. The benefit of long-term low-dose acyclovir should be confirmed prospectively. Bone Marrow Transplantation (2001) 28, 689â692.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients Biol Blood Marrow Transplant 2000 6: 219â230
Shepp DH, Dandliker PS, Meyers JD . Treatment of varicella-zoster virus infection in severely immunocompromised patients: a randomized comparison of acyclovir and vidarabine New Engl J Med 1986 314: 208â212
Ljungman P, Wilczek H, Gahrton G et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro Bone Marrow Transplant 1986 1: 185â192
Selby PJ, Powles RL, Easton D et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation Br J Cancer 1989 59: 434â438
Perren TJ, Powles RL, Easton D et al. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation Am J Med 1988 85 (Suppl.â2A): 99â101
Sempere A, Sanz GF, Senent L et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia Bone Marrow Transplant 1992 10: 495â498
Steer CB, Szer J, Sasadeusz J et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir Bone Marrow Transplant 2000 25: 657â664
Kanda Y, Mineishi S, Saito T et al. Pre-emptive therapy against cytomegalovirus (CMV) diseases guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan Bone Marrow Transplant 2001 27: 437â444
Wilson A, Sharp M, Koropchak CM et al. Subclinical varicella-zoster virus viremia, herpes zoster, and T-lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation J Infect Dis 1992 165: 119â126
Ellis MN, Martin JL, Lobe DC et al. Induction of acyclovir-resistant mutants of herpes simplex virus type I in athymic nude mice J Antimicrob Chemother 1986 18 (Suppl.âB): 95â101
Beutner KR, Friedman DJ, Forszpaniak C et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults Antimicrob Agents Chemother 1995 39: 1546â1553
Tyring S, Barbarash RA, Nahlik JE et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial: Collaborative Famciclovir Herpes Zoster Study Group Ann Intern Med 1995 123: 89â96
Balfour HH, Benson C, Baun J et al. Management of acyclovir-resistant herpes simplex and varicella-zoster infections J Acquired Immune Defic Syndr 1994 7: 254â260
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kanda, Y., Mineishi, S., Saito, T. et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28, 689â692 (2001). https://doi.org/10.1038/sj.bmt.1703214
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703214
Keywords
This article is cited by
-
Impfen bei Immundefizienz
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2020)
-
Successful management of visceral disseminated varicella zoster virus infection during treatment of membranous nephropathy: a case report
BMC Infectious Diseases (2019)
-
Predicting risk factors for varicella zoster virus infection and postherpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysis
Annals of Hematology (2017)
-
Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
BMC Infectious Diseases (2017)
-
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
Annals of Hematology (2016)